Ultragenyx agrees to sell priority review voucher for $210 million
Ultragenyx said it has entered a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for $210 million. Closing is subject to customary conditions, including the Hart-Scott-Rodino waiting period.